Biotech | March 01, 2022
AstraZeneca and Neurimmune enter licencing agreement to develop and commercialise NI006
Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m
Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m
Thermo Fisher and Symphogen extend their collaboration using innovative and efficient workflows to improve data confidence, aiding the creation of new cancer treatments
The joint initiative is called J-ARC Healthcare Solutions
UNICOR-v has the potential to protect against future epidemics caused by a coronavirus jumping from animals to humans, but also against new variants emerging from SARS-Cov-2
Dr. Shah will lead strategic and operational clinical development of the company's diverse pipeline
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan
Subscribe To Our Newsletter & Stay Updated
